Zimbabwe has turned down a major US healthcare agreement worth 367 million US dollars (272 million pounds) spanning five years over the United States' request for sensitive biological samples.
This move came to light after a government memo dated December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the agreement was "lopsided".
An official spokesman later stated that the US was demanding access to genetic material for research and commercial purposes while was not willing to share the benefits from future treatments.
"We will now turn to the difficult and regrettable process of ending our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has appealed for continued negotiations to secure a deal acceptable to both sides so the country's vital HIV treatment initiative can proceed.
Broader Background
This development comes after a similar case in Kenya, where a court halted a similar health funding agreement following concerns were filed about the safety of Kenyans' health data.
Since returning to office last year, US President Donald Trump has drastically cut overseas assistance and closed the key foreign aid agency.
The agency had administered aid for the US government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral agreements to enhance transparency and responsibility.
According to statements, Sixteen nations in Africa have so far signed these new health pacts, constituting over $18.3bn in new funding.
Specifics of the Rejected Agreement
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration would have delivered immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving antiretroviral therapy through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to provide its biological resources and data for a long time, with no equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that shared data," Mangwana explained.
"Put simply, our nation would supply the raw materials for scientific discovery without any assurance that the resulting innovations would be available to our citizens should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further noted that the US's withdrawal from the global health body and its push of one-on-one health agreements were undermining systems already set up via the international health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework designed to manage future global health emergencies.
"This mechanism is intended to guarantee that when a nation contributes its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the resources to create them."
The government's concerns over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We are open to further dialogue with our US partners on how future co-operation might be arranged in a way that honours the sovereignty and dignity of both nations."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but suggested that negotiations should continue since a large portion of the country's Aids initiatives relied on international support.
"If technical issues arise, including those involving information security or agreement terms, these can frequently be resolved via technical clarification and negotiated safeguards," it said.
This impasse underscores the complex debate between accepting crucial international aid and protecting a country's data in an increasingly data-driven world.